-
71.发明授权公开(公告)号：US09572865B2
公开(公告)日：2017-02-21
申请号：US13460342
申请日：2012-04-30
Applicant: John Knopf , Jasbir Seehra , Ravindra Kumar
Inventor： John Knopf , Jasbir Seehra , Ravindra Kumar
CPC classification number: C07K16/3061 , A61K38/179 , A61K38/1796 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K14/71 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/54 , C07K2317/55 , C07K2317/622 , C07K2319/02 , C07K2319/30
Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma.
Abstract translation: 在某些方面，本发明提供用于促进骨生长和增加骨密度以及用于治疗多发性骨髓瘤的组合物和方法。
-
公开(公告)号：US08703927B2
公开(公告)日：2014-04-22
申请号：US13542269
申请日：2012-07-05
Applicant: Jasbir Seehra , Robert Scott Pearsall , Ravindra Kumar
Inventor： Jasbir Seehra , Robert Scott Pearsall , Ravindra Kumar
IPC: C07H21/04
CPC classification number: C07K14/495 , A61K31/00 , A61K31/454 , A61K31/7068 , A61K38/1709 , A61K38/179 , A61K38/1796 , A61K38/1816 , A61K38/193 , A61K39/39533 , A61K45/06 , C07K14/475 , C07K14/505 , A61K2300/00
Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Abstract translation: 在某些方面，本发明提供用于增加脊椎动物（包括啮齿动物和灵长类动物，特别是人）中红细胞和/或血红蛋白水平的组合物和方法。
-
公开(公告)号：US08703694B2
公开(公告)日：2014-04-22
申请号：US13403657
申请日：2012-02-23
Applicant: John Knopf , Jasbir Seehra , Ravindra Kumar
Inventor： John Knopf , Jasbir Seehra , Ravindra Kumar
CPC classification number: C07K16/40 , A61K31/7088 , A61K38/00 , A61K38/1796 , A61P3/00 , A61P3/04 , A61P3/10 , A61P21/00 , C07K14/71 , C07K2319/30 , C12N5/0602
Abstract: In certain aspects, the present invention provides compositions and methods for increasing thermogenic adipocytes (e.g., brown adipocytes or other UCP-1 expressing adipocytes) by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, anti-Nodal, anti-activin, and anti-GDF 11 antibodies. A variety of metabolic and other disorders may be treated by causing an increase in thermogenic adipocytes.
Abstract translation: 在某些方面，本发明提供通过施用ActRIIB信号传导途径的拮抗剂来增加产热脂肪细胞（例如，棕色脂肪细胞或其他表达UCP-1的脂肪细胞）的组合物和方法。 这些拮抗剂的实例包括ActRIIB多肽，抗ActRIIB抗体，抗肌生成抑制素抗体，抗GDF3抗体，抗-Nodal，抗激活素和抗GDF11抗体。 可以通过引起生热脂肪细胞的增加来治疗各种代谢和其它疾病。
-
公开(公告)号：US20130344067A1
公开(公告)日：2013-12-26
申请号：US13907798
申请日：2013-05-31
Applicant: Asya Grinberg , John Knopf , Robert S. Pearsall , Ravindra Kumar , Jasbir Seehra
Inventor： Asya Grinberg , John Knopf , Robert S. Pearsall , Ravindra Kumar , Jasbir Seehra
IPC: A61K39/395 , A61K45/06 , C07K16/18
CPC classification number: A61K39/39558 , A61K45/06 , C07K14/71 , C07K16/18 , C07K2317/52 , C07K2319/30
Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and antibodies that inhibit receptor-ligand interaction.
Abstract translation: 在某些方面，本公开涉及以下认识：包含活化素样激酶I（ALK1）多肽的细胞外结构域的配体结合部分的多肽可用于抑制体内血管发生，特别是在血管生成相关的哺乳动物中 疾病 该公开内容还鉴定了ALK1的配体，并证明这些配体具有促血管生成活性，以及抑制受体 - 配体相互作用的抗体。
-
75.发明申请METHODS FOR INCREASING RED BLOOD CELL LEVELS AND TREATING ANEMIA USING A COMBINATION OF GDF TRAPS AND ERYTHROPOIETIN RECEPTOR ACTIVATORS 有权使用GDF TRAPS和ERYTHROPOIETIN受体激活剂组合增加红血球细胞水平和治疗神经痛的方法公开(公告)号：US20130071393A1
公开(公告)日：2013-03-21
申请号：US13542269
申请日：2012-07-05
Applicant: Jasbir Seehra , Robert Scott Pearsall , Ravindra Kumar
Inventor： Jasbir Seehra , Robert Scott Pearsall , Ravindra Kumar
IPC: A61K38/17 , A61K39/395 , A61K38/18
CPC classification number: C07K14/495 , A61K31/00 , A61K31/454 , A61K31/7068 , A61K38/1709 , A61K38/179 , A61K38/1796 , A61K38/1816 , A61K38/193 , A61K39/39533 , A61K45/06 , C07K14/475 , C07K14/505 , A61K2300/00
Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.
Abstract translation: 在某些方面，本发明提供用于增加脊椎动物（包括啮齿动物和灵长类动物，特别是人）中红细胞和/或血红蛋白水平的组合物和方法。
-
Patent Agency Ranking
公开(公告)号：US08343933B2
公开(公告)日：2013-01-01
申请号：US12893976
申请日：2010-09-29
Applicant: John Knopf , Jasbir Seehra , Ravindra Kumar
Inventor： John Knopf , Jasbir Seehra , Ravindra Kumar
IPC: A61K38/16 , C07K14/00 , C07K14/705 , C07K14/71
CPC classification number: C07K14/71 , A61K38/00 , C07K14/705 , C07K14/72 , C07K16/18 , C07K2319/30 , C07K2319/70
Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand.
Abstract translation: 在某些方面，本发明提供用于调节（促进或抑制）组织如骨，软骨，肌肉，脂肪和/或神经元组织的生长的组合物和方法。 本发明还提供筛选调节ActRIIB蛋白和/或ActRIIB配体的活性的化合物的方法。 本文提供的组合物和方法可用于治疗与ActRIIB蛋白和/或ActRIIB配体的异常活性相关的疾病。
-
公开(公告)号：US08232252B2
公开(公告)日：2012-07-31
申请号：US12167705
申请日：2008-07-03
Applicant: Glenn R. Larsen , Dianne S. Sako , Xiao-Jia Chang , Geertruida M. Veldman , Dale Cumming , Ravindra Kumar , Gray Shaw
Inventor： Glenn R. Larsen , Dianne S. Sako , Xiao-Jia Chang , Geertruida M. Veldman , Dale Cumming , Ravindra Kumar , Gray Shaw
IPC: A61K38/10 , A61K38/16 , C07K7/08 , C07K14/435 , C12N15/09
CPC classification number: C07K14/005 , A61K38/00 , A61K39/00 , C07K14/4703 , C07K14/51 , C07K14/52 , C07K14/5431 , C07K14/705 , C07K16/2851 , C07K16/2854 , C07K19/00 , C07K2319/00 , C07K2319/24 , C12N9/10 , C12N9/1051 , C12N9/6454 , C12N2770/36222
Abstract: A novel P-selectin ligand glycoprotein is disclosed, comprising the amino acid sequence set forth in SEQ ID NO:2 or by the amino acid sequence set forth in SEQ ID NO:4. DNA sequences encoding the P-selectin ligand protein are also disclosed, along with vectors, host cells, and methods of making the P-selectin ligand protein. Pharmaceutical compositions containing the P-selectin ligand protein and methods of treating inflammatory disease states characterized by P-selectin- and E-selectin-mediated intercellular adhesion are also disclosed.
Abstract translation: 公开了一种新型P-选择蛋白配体糖蛋白，其包含SEQ ID NO：2所示的氨基酸序列或SEQ ID NO：4所示的氨基酸序列。 还公开了编码P-选择素配体蛋白的DNA序列，以及载体，宿主细胞和制备P-选择蛋白配体蛋白的方法。 还公开了含有P-选择素配体蛋白质的药物组合物和治疗由P-选择蛋白和E-选择素介导的细胞间粘附特征的炎性疾病状态的方法。
-
公开(公告)号：US20120156204A1
公开(公告)日：2012-06-21
申请号：US13404593
申请日：2012-02-24
Applicant: Jasbir Seehra , Ravindra Kumar , Jennifer Lachey , Alan Koncarevic
Inventor： Jasbir Seehra , Ravindra Kumar , Jennifer Lachey , Alan Koncarevic
CPC classification number: C07K16/40 , A61K31/00 , A61K31/7088 , A61K38/179 , A61K2039/505 , C07K14/705 , C07K16/22 , C07K2317/24 , C07K2317/31 , C07K2317/54 , C07K2317/55 , C07K2317/622 , C07K2317/76 , C07K2319/30
Abstract: In certain aspects, the present invention provides compositions and methods for increasing adiponectin in a patient in need thereof by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-activin A and/or B antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, and anti-BMP7 antibodies. Also provided are methods for ameliorating one or more undesired effects of anti-androgen therapy, including muscle loss, bone loss, increased adiposity, and/or increased insulin resistance. A variety of disorders may be treated by causing an increase in circulating adiponectin concentrations.
Abstract translation: 在某些方面，本发明提供了通过施用ActRIIB信号通路的拮抗剂来增加有需要的患者中的脂连蛋白的组合物和方法。 此类拮抗剂的实例包括ActRIIB多肽，抗ActRIIB抗体，抗激活素A和/或B抗体，抗肌生成抑制素抗体，抗GDF3抗体和抗BMP7抗体。 还提供了用于改善一种或多种不期望的抗雄激素治疗效果的方法，包括肌肉损失，骨丢失，增加的肥胖和/或增加的胰岛素抵抗。 可以通过引起循环中脂联素浓度的增加来治疗多种疾病。
-
79.发明授权Activin-ActRIIa antagonists and uses for treating multiple myeloma 有权Activin-ActRIIa拮抗剂和治疗多发性骨髓瘤的用途公开(公告)号：US08173601B2
公开(公告)日：2012-05-08
申请号：US12012525
申请日：2008-02-01
Applicant: John Knopf , Jasbir Seehra , Ravindra Kumar
Inventor： John Knopf , Jasbir Seehra , Ravindra Kumar
CPC classification number: C07K16/3061 , A61K38/179 , A61K38/1796 , A61K39/39558 , A61K45/06 , A61K2039/505 , C07K14/71 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/54 , C07K2317/55 , C07K2317/622 , C07K2319/02 , C07K2319/30
Abstract: In certain aspects, the present invention provides compositions and methods for promoting bone growth and increasing bone density, as well as for the treatment of multiple myeloma.
Abstract translation: 在某些方面，本发明提供用于促进骨生长和增加骨密度以及用于治疗多发性骨髓瘤的组合物和方法。
-
公开(公告)号：US08138142B2
公开(公告)日：2012-03-20
申请号：US12657146
申请日：2010-01-13
Applicant: Jasbir Seehra , Ravindra Kumar , Jennifer Lachey , Alan Koncarevic
Inventor： Jasbir Seehra , Ravindra Kumar , Jennifer Lachey , Alan Koncarevic
CPC classification number: C07K16/40 , A61K31/00 , A61K31/7088 , A61K38/179 , A61K2039/505 , C07K14/705 , C07K16/22 , C07K2317/24 , C07K2317/31 , C07K2317/54 , C07K2317/55 , C07K2317/622 , C07K2317/76 , C07K2319/30
Abstract: In certain aspects, the present invention provides compositions and methods for increasing adiponectin in a patient in need thereof by administering an antagonist of an ActRIIB signaling pathway. Examples of such antagonists include ActRIIB polypeptides, anti-ActRIIB antibodies, anti-activin A and/or B antibodies, anti-myostatin antibodies, anti-GDF3 antibodies, and anti-BMP7 antibodies. Also provided are methods for ameliorating one or more undesired effects of anti-androgen therapy, including muscle loss, bone loss, increased adiposity, and/or increased insulin resistance. A variety of disorders may be treated by causing an increase in circulating adiponectin concentrations.
Abstract translation: 在某些方面，本发明提供了通过施用ActRIIB信号通路的拮抗剂来增加有需要的患者中的脂连蛋白的组合物和方法。 此类拮抗剂的实例包括ActRIIB多肽，抗ActRIIB抗体，抗激活素A和/或B抗体，抗肌生成抑制素抗体，抗GDF3抗体和抗BMP7抗体。 还提供了用于改善一种或多种不期望的抗雄激素治疗效果的方法，包括肌肉损失，骨丢失，增加的肥胖和/或增加的胰岛素抵抗。 可以通过引起循环中脂联素浓度的增加来治疗多种疾病。
-
-
-
-
-
-
-
-
-
Search Results
90
records
(took 0.055 seconds)
